Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.

ABSTRACT: Multidrug-resistant tuberculosis (MDR-TB) is a major health threat worldwide, causing a significant economic burden to patients and their families. Due to the longer duration of treatment and expensive second-line medicine, the economic burden of MDR-TB is assumed to be higher than drug-susceptible TB. However, the costs associated with MDR-TB are yet to be comprehensively quantified. We conducted this systematic review and meta-analysis to determine the global burden of catastrophic costs associated with MDR-TB on patients and their households. We systematically searched five databases (CINHAL, MEDLINE, Embase, Scopus, and Web of Science) from inception to 2 September 2022 for studies reporting catastrophic costs on patients and affected families of MDR-TB. The primary outcome of our stud

SUBMITTER: Akalu TY 

PROVIDER: S-EPMC10724290 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature